Merck Says Its Covid Pill Is Less Effective in a Final Analysis
byOne Preparation-
0
The drug, molnupiravir, reduced the risk of hospitalization and death in high-risk Covid patients by 30 percent. An earlier analysis had found a 50 percent reduction.
